MGI的动态

I am hearing that globally there is an urgent need for increased throughput and capacity in bioanalytical laboratories - is this something we see in Australia and New Zealand for protein biomarker quantification? Let me know if you want to do this! https://lnkd.in/gHu5EzVw #SCIEX #EchoMSPlus #PowerOfPrecision

???????????????????? ?????????????? ?????????????????????? - ?? ?????????????? ???????????? ?????????????????????? ?? Download PDF Brochure: https://lnkd.in/d5yaXPY4 The Infectious Disease Diagnostics market is on a remarkable trajectory, with projections that underscore its critical importance in global healthcare: ?? Market Snapshot: - Current Value (2023): USD 21.4 billion - Projected Value (2028): USD 31.5 billion - Compound Annual Growth Rate (CAGR): 8.0% Key Market Drivers Propelling Growth: ? Increasing prevalence of infectious diseases worldwide ? Significant investments in R&D for diagnostic products ? Growing awareness of early disease detection ? Technological innovations in diagnostic technologies ? Shift towards decentralized Point-of-Care (PoC) testing The market spans a comprehensive range of products and services, including: - Reagents & Diagnostic Kits - Laboratory and Point-of-Care Testing - Diverse Sample Types (Blood, Urine) - Advanced Technologies (Immunodiagnostics, NGS, PCR) - Diagnostics for Diseases like Hepatitis, HIV, HPV, and more ?????? ?????????????????? ???????????????? ???? ???????? ???????????? ??????????????: Abbott, Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux, Siemens Healthineers, Danaher Corporation, Hologic, Inc., BD, Revvity, QIAGEN, Seegene Inc., Grifols, Diasorin, Bio-Rad Laboratories, Sysmex Corporation, QuidelOrtho, Meridian Bioscience Inc., Genetic Signatures, OraSure Technologies, Trinity Biotech, Chembio Diagnostics, Inc., Co-Diagnostics, Inc, ELITechGroup - A Bruker Company, Epitope Diagnostics, Inc., Trivitron Healthcare, Meril Life Sciences Pvt. Ltd. (India), InBios International, Inc., Vela Diagnostics, and Uniogen Other Companies that are Operating in this Market Globally: Alere Inc. BioFire Diagnostics, LLC Quidel Meridian Bioscience Inc. GenMark Diagnostics Magnolia Medical Technologies Biocartis Immunodiagnostic Systems (IDS) Trinity Biotech Medsource Ozone Biomedicals Pvt. Ltd. BioPerfectus DSS Imagetech Pvt Ltd Ellume #Healthcare #MedicalDiagnostics #InfectiousDiseases #HealthTech #GlobalHealth

Source: Future microbiology This study compares the diagnostic abilities of Fourier transform infrared spectroscopy (FT-IR) with MALDI-TOF mass spectrometry (MS) and whole-genome sequencing (WGS) for bacterial discrimination. The study analyzed 104 pathogenic isolates of Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. The overall prediction accuracy was 99.6% for FT-IR and 95.8% for MALDI-TOF-MS. FT-IR showed superior analysis of N. meningitidis serogroups compared to MALDI-TOF-MS. The phylogenetic relationship of S. pyogenes was similar between FT-IR and WGS, but not for S. aureus or S. pneumoniae. Clinical severity was associated with specific genes in S. pneumoniae and S. aureus through WGS. FT-IR shows promise as a diagnostic tool and warrants further evaluation.

?? Discover Accurate HBoV Detection with Our PCR-Fluorescence Probe Kit! ?? ? ?Lyophilized Form ??No cold-chain transportation required ? Specification：48T/Kit Molecular biotechnology：Real-Time PCR Storage：-25℃ to 8℃ and is valid for 18 months Applicable PCR：Hecin UltraFast QPCR HC1600; ABI 7500 Real-Time PCR System; Bio-rad CFX96; LAN Real-Time PCR, ect. ? ?? Intended Use: Our HBoV Nucleic Acid Test Kit is designed for qualitative detection of Human Bocavirus (HBoV) nucleic acid in human oropharyngeal swab specimens. HBoV infections present as rhinitis, pharyngitis, pneumonia, and gastroenteritis, with symptoms like cough, dyspnea, fever, nausea, and diarrhea. Common in 1%-10% of respiratory specimens from children and adults, HBoV belongs to the Parvoviridae family and spreads through respiratory inhalation or contact with infectious matter. Suitable for auxiliary diagnosis, clinical correlation is necessary to determine infection status. Positive results don't exclude bacterial or other viral co-infections. Only qualified, trained personnel should use this kit for in vitro diagnostic use. ? ? Test Principle: Leveraging real-time fluorescent PCR technology, our kit targets the highly conserved VP gene sequence in HBoV. With specific primers and TaqMan fluorescent probes (FAM fluorescein, 78bp amplification fragment), rapid detection is achieved through PCR amplification in an amplification tube. The entire process is monitored by exogenous internal control (M13 pseudoviral particle, ROX fluorescein, 74bp amplification fragment) and external quality controls (positive and negative controls), ensuring accuracy and reliability. ?? Contact us: [email protected] ?? Discover more: hecin-scientific.com/en ? #HBoVDetection #PCRKit #FluorescentProbe #RealTimePCR #MolecularDiagnostics #ClinicalLaboratory #InVitroDiagnostics #InfectiousDiseaseTesting

Fascinating! My microbiology training makes it easy to see these as plasmid analogs promoting survival, virulence and replication. Super curious to see how this understanding develops, ideally for therapeutic intervention. https://lnkd.in/etkmmk4m

?? Revolutionizing Biomarker Quantification with Acoustic Ejection Mass Spectrometry (AEMS) ?? The global scientific response to COVID-19 underscored the urgent need for increased throughput in bioanalytical laboratories. Acoustic ejection mass spectrometry (AEMS) emerges as a game-changer, offering ultra-fast and precise protein biomarker quantification. This innovative technology enables rapid screening of acute phase response (APR) protein markers from plasma and SARS-CoV-2 peptides from nasopharyngeal swabs, achieving unprecedented speed and accuracy. Key highlights include: Quantification of APR proteins in 267 plasma samples in just 4.8 hours. SARS-CoV-2 peptide quantification from 145 viral swabs in only 10 minutes. AEMS offers a 15-fold speed improvement over traditional LC-MS methods. This breakthrough in bioanalytical technology promises to enhance the efficiency and reliability of large-scale biomarker screening, paving the way for faster and more accurate disease diagnostics. #BiomarkerQuantification #AEMS #COVID19 #BioanalyticalScience #HealthcareInnovation https://lnkd.in/d6XS7Hbi

Unified metagenomic method for rapid detection of microorganisms in clinical samples Clinical metagenomics involves the genomic sequencing of all microorganisms in clinical samples ideally after depletion of human DNA to increase sensitivity and reduce turnaround times. Current human DNA depletion methods preferentially preserve either DNA or RNA containing microbes, but not both simultaneously. Here we describe and present data using a practical and rapid mechanical host-depletion method allowing simultaneous detection of RNA and DNA microorganisms linked with nanopore sequencing. Although further workflow refinement and validation on samples containing a broader range of pathogens is required, it holds promise as a clinically deployable workflow suitable for evaluation in routine microbiology laboratories. https://lnkd.in/gJXfbafJ

Antibiotic resistance poses a significant threat to global health, with projections suggesting it could become the leading cause of death by 2050. Recent research has identified a genetic signature in bacteria that predicts their likelihood of developing drug resistance. This discovery, centered on Pseudomonas aeruginosa, highlights the potential for precision-based treatments by identifying bacterial "fingerprints" through DNA sequencing. Such advancements could lead to more accurate diagnostics and reduce antibiotic misuse, addressing a critical need in combating treatment-resistant infections. The development of diagnostic tools based on these findings could significantly impact patient care and antibiotic stewardship.

Breaking news: QuickMIC? proves superior speed and performance in a multicenter study! ?? We’re proud to announce a new scientific publication of the QuickMIC? system, today's fastest diagnostic system on the market for antibiotic susceptibility testing (AST) of blood cultures from sepsis patients. ?? The multicenter study evaluated the performance of the QuickMIC system in terms of speed, precision, accuracy, and reproducibility compared to the reference method broth microdilution (BMD). The study contains an extensive collection of clinical samples, including challenging strains totalling 559 different organisms, and was conducted in collaboration with three leading European hospitals. ?? Clinical study data shows that QuickMIC is highly accurate compared to the reference testing method for AST. QuickMIC provides 95.6% agreement with the reference MIC values (Minimum Inhibitory Concentration) and over two times higher precision than BMD. The mean analysis time was 3h and 13 min. Read the whole press release here ?? https://lnkd.in/dkxbTQJS #clinicalmicrobiology #research #sepsis #diagnostics

Exciting News! The Annual Summit on Biopharmaceutical Product Development is just around the corner! After the tremendous success of last year's event—where industry and academic leaders came together to discuss cutting-edge vaccine innovations—I’m confident that this year’s summit, organized by Ratnesh Jain and his team, will be just as impactful. This is a must-attend event for anyone passionate about the future of #vaccine science and #biopharmaceutical advancements. Don’t miss the opportunity to dive deep into several interesting topics on biologics including: Vaccine design and innovation; Next-generation #TCell-based assays; New technologies in vaccine research etc. It’s also a fantastic chance to network with global experts, share knowledge, and collaborate on shaping the future of healthcare. Please follow the details from Biologics Workshop #Vaccine #TCell #Bioassays #Immunology #Biopharma #Innovation